Start Your Risk-Free Subscription

Login

The Daily Biopharmaceutical News Source

Advanced Search

Strong Phase II Resminostat Data Send 4SC Shooting Up

By Cormac Sheridan
BioWorld International Correspondent

Wednesday, January 25, 2012

Shares in 4SC AG surged more than 38 percent last week on news that its histone deacetylase (HDAC) inhibitor resminostat hit the primary endpoint of a Phase II trial in advanced hepatocellular carcinoma (HCC).

To continue reading subscribe now to BioWorld International

Learn More about BioWorld International

Already a subscriber? Sign In or Buy now to activate your subscription

»

Login or register to post comments

Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5476
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST

BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA

Part of Thompson Media Group LLC
Thompson.com | Sheshunoff.com | ASPratt.com | AHCMedia.com | BioWorld.com | CMEweb.com | ThePerformanceInstitute.org | ASMIweb.com

Editorial Guidelines

For Site License Discounts, please contact Customer Service at (800) 477-6307 or customerservice@bioworld.com.